title: Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Study.
abstract: Anti-N-methyl-D-aspartate receptor encephalitis is an autoimmune syndrome that presents with personality changes, autonomic dysfunction, and neurologic deterioration. Most patients with this syndrome progress from psychosis to seizure to catatonia, often associated with abnormal movements, autonomic instability, and hypoventilation. First-line treatment constitutes resection of the associated neoplasm, corticosteroids, intravenous immunoglobulin, and plasma exchange. Second-line treatment includes rituximab and cyclophosphamide. A case of confirmed anti-N-methyl-D-aspartate receptor encephalitis is presented that illustrates the diagnostic and treatment challenges associated with this syndrome and underscores the nursing implications of medical management during immunosuppression. This case study recommends surface cooling and a pharmaceutical regimen for management of autonomic storming, which is a hallmark of this disorder.
authors: Roger Kelsey
authors: RK
authors: Halbert
mesh_terms: D000328:Adult; D060426:Anti-N-Methyl-D-Aspartate Receptor Encephalitis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000927:Anticonvulsants / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006261:Headache / Q000209:etiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077287:Levetiracetam; D010051:Ovarian Neoplasms / Q000601:surgery; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy*
chemical_list: D000927:Anticonvulsants; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000077287:Levetiracetam; D000069283:Rituximab; D003520:Cyclophosphamide; D010889:Piracetam